Robert Christopher Cook, Chief Operating and Legal Officer of Filana Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing an open-market purchase of 121,575 shares of common stock on November 16, 2026, at a weighted average price of $0.46 per share.
Key Highlights
- Shares purchased: 121,575 shares of common stock acquired on November 16, 2026, with transaction code P (purchase).
- Weighted average price: $0.46 per share, representing purchases made across multiple open-market transactions ranging from $0.40 to $0.48 per share.
- Resulting ownership: Following the transaction, Cook directly holds 135,300 shares of common stock, according to the filing.
- Reporting person role: Cook is identified in the filing as Chief Operating and Legal Officer of Filana Therapeutics, Inc.
- Issuer and ticker: The filing identifies the issuer as Filana Therapeutics, Inc., trading on NASDAQ:FLNA.
Cook's Open-Market Purchase of Filana Therapeutics Common Stock
According to the Form 4 filed with the SEC on November 18, 2026, Robert Christopher Cook, Chief Operating and Legal Officer of Filana Therapeutics, Inc. (NASDAQ:FLNA), reported acquiring 121,575 shares of the company's common stock on November 16, 2026. The filing records the transaction under code P, indicating an open-market purchase. The reported price of $0.46 is a weighted average across multiple transactions.
The filing includes a footnote stating that "the purchase reported in column 4 is a weighted average price," and that the shares were purchased in multiple open-market transactions at prices ranging from $0.40 to $0.48 per share. The filing further notes that Cook "undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote."
Following the reported transaction, the filing discloses that Cook directly and beneficially owns 135,300 shares of Filana Therapeutics common stock. The Form 4 was signed by Eric J. Schoen by Power of Attorney on November 18, 2026, and indicates this was a filing by one reporting person. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Filana Therapeutics' Chief Operating and Legal Officer disclosed a purchase of 121,575 shares of common stock on November 16, 2026, at a weighted average price of $0.46 per share, resulting in direct beneficial ownership of 135,300 shares.




Please wait processing your request...